Skip to content
Open access

Protease-Responsive Condensation of Engineered Proteins Drives Tumor-Targeted T-Cell Activation.

Oct 2026 · Angewandte Chemie · 0 citations · 27 references
Medicine

TL;DR

A masked extracellular phase-separation platform (Condenstim) is engineered enabling tumor microenvironment-specific condensate formation and establishes a generalizable strategy to control extracellular LLPS for both fundamental studies and therapeutic applications.

Abstract

Liquid-liquid phase separation (LLPS) drives the formation of biomolecular condensates, which are fundamental to cell signaling. Extracellular phase separation is emerging as a potent strategy for cell-specific signaling modulation; however, its application is limited by the lack of control over on-demand condensate formation. Here, we engineered a masked extracellular phase-separation platform (Condenstim) enabling tumor microenvironment-specific condensate formation. To achieve this, we first developed an LLPS-based system that clusters CD3 and CD28 receptors to assemble synthetic immunological synapses for potent T-cell activation. By employing a protease-cleavable linker for site-specific PEGylation, we sterically shielded the protein building blocks, rendering the platform biologically dormant during systemic circulation. Within the tumor microenvironment, localized proteases cleave the linker, thereby restoring LLPS in situ. This modular design ensures spatially confined and efficient T-cell activation, leading to robust tumor regression in murine models, both as a monotherapy and in combination with PD-1 blockade. Our findings establish a generalizable strategy to control extracellular LLPS for both fundamental studies and therapeutic applications.

Read PDF

Similar papers

Oct 2026

A dual-gated engineered bacterial platform for spatiotemporally controlled precise protein degradation.

Lysosome-targeting chimeras (LYTACs) have attracted much attention due to their ability to specifically target and degrade disease-related proteins on the cell membrane. However, their clinical application is limited by poor tumor specificity, systemic off-target effects, and a lack of temporal regulation. Engineered b...

Shan Sun, Ruo-Xi Hu, Xue Zhai et al. · 0 citations
Review Open access Oct 2026

Liquid-liquid phase separation in cancer radiotherapy and immunotherapy: emerging roles and translational opportunities

Liquid-liquid phase separation (LLPS) is a physicochemical process through which biomolecules assemble into membraneless condensates via weak, multivalent interactions. LLPS has emerged as a central biological principle that helps explain intracellular spatiotemporal compartmentalization, signal transduction, and str...

Chen-Cheng Dong, Cong Shang, Bing-Ran Han et al. · 0 citations
Open access Oct 2026

Dual-State Tumor-Activated RNA Delivery for Tumor-Selective and Precision Therapy.

D-STAR establishes a dual-state adaptive RNA delivery framework that decouples systemic stability from activation potency, thereby offering a generalizable strategy for context-responsive precision RNA therapeutics.

Yuan-Shuai Song, Tian Jiang, Xin Shen et al. · 0 citations
Oct 2026

Molecularly nanoengineered dendritic cells for tumor-specific antigen capture and sono-activatable cytokine-mediated immunotherapy.

Engineering artificial dendritic cells (DCs) holds great promise for cancer immunotherapy, but achieving spatiotemporally controlled multifunctionality within the immunosuppressive tumor microenvironment remains a challenge. Here, we report a chemically engineered, ultrasound (US)-activatable artificial DCs nanosystem...

Ning-Yue Yu, Sheng-Ze Lu, Bing Xiao et al. · 0 citations
Review Open access Oct 2026

Engineering Cell-Free Protein Synthesis Within Protocells.

Cell-free protein synthesis (CFPS) has emerged as a versatile platform for producing proteins in vitro with exceptional programmability, rapid prototyping capability, and an open biochemical environment. However, conventional CFPS is typically performed in homogeneous solutions that lack the spatial organization, molec...

Yan-Peng Xi, Lei Liu, Meng-Yue Zhu et al. · 0 citations
Oct 2026

Terminal-overhang-restricted CRISPR logic nanodevice for precision cancer therapy.

The limited precision of controlled drug release remains a major challenge for precision cancer therapy. Herein, a protein and nucleic acid dual-biomarker-responsive CRISPR AND logic nanodevice, termed LogiCas, is developed by integrating APE1 and miRNA-21 as dual inputs for precise tumor therapy. Leveraging the string...

Jing-Ge Zhang, Yu-He Yang, Yong-Hua Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.